Fact-checked by Grok 2 weeks ago

Coccidioides

Coccidioides is a genus of dimorphic ascomycetous fungi consisting of two closely related species, Coccidioides immitis and Coccidioides posadasii, that are the causative agents of coccidioidomycosis, a potentially severe respiratory infection also known as Valley Fever.^[1]^[2] These soil-dwelling fungi exist in a saprophytic mycelial form in the environment and transform into parasitic spherules within mammalian hosts, with arthroconidia serving as the primary infectious propagules inhaled from airborne dust.^[1]^[3] Endemic to arid and semiarid regions of the Western Hemisphere, particularly the southwestern United States, northern Mexico, and parts of Central and South America, Coccidioides species thrive in alkaline soils with high salinity and low organic matter, often associated with rodent burrows and disturbed habitats. Incidence has been increasing in recent years, potentially linked to climate change (as of 2025).^[2]^[1]^[4] The two species, phenotypically indistinguishable but differentiated by molecular methods, diverged approximately 5 million years ago, with C. immitis primarily in California and C. posadasii distributed more broadly across endemic areas.^[2]^[5] Genetic studies reveal a genome of approximately 27–29 Mb with evidence of cryptic sexual recombination via mating-type loci.^[3] Epidemiologically, coccidioidomycosis affects an estimated 200,000–350,000 people annually in the United States, though only about 20,000–25,000 cases are reported (as of 2023), with approximately 60% of infections remaining asymptomatic.^[2]^[6] Transmission occurs solely through environmental exposure, with no person-to-person spread, and risk factors include dust inhalation during activities like construction, agriculture, or natural disasters; incidence is higher among older adults and immunocompromised individuals, where dissemination can occur in less than 5% of cases and prove fatal.^[1]^[7] Diagnosis relies on serology, culture, or histopathology, while treatment involves azole antifungals like fluconazole for mild cases or amphotericin B for severe disseminated disease.^[1]

Taxonomy and Phylogeny

Classification

The genus Coccidioides belongs to the kingdom Fungi, phylum Ascomycota, subphylum Pezizomycotina, class Eurotiomycetes, order Onygenales, and family Onygenaceae.^[8]^[9] The genus was established in 1896 by Rixford and Gilchrist to describe the causative agent of coccidioidomycosis, initially observed in human tissue samples resembling protozoan coccidia.^[10] Phylogenetically, Coccidioides is positioned among dimorphic ascomycetes in the Onygenales, sharing close relationships with genera such as Histoplasma and Blastomyces, which also cause systemic mycoses in mammals. This affiliation is supported by molecular analyses of ribosomal internal transcribed spacer (ITS) regions and beta-tubulin genes, which reveal conserved sequences indicative of a common ancestry within the order.^[3] The two main pathogenic species in the genus, C. immitis and C. posadasii, diverged approximately 5 million years ago based on genomic analyses.^[11] Whole-genome sequencing has illuminated evolutionary adaptations enabling Coccidioides dimorphism and persistence in arid soils, including contractions in gene families for plant cell wall degradation (e.g., glycosyl hydrolases) and expansions in animal tissue proteases (e.g., S8 and M35 families), facilitating a shift from saprophytic to parasitic nutrition.^[12] These changes, alongside conserved virulence regulators like HSP90 and expansions in FunK1 protein kinases, underpin the thermal dimorphic switch between environmental mycelia and host spherules, while losses in certain nutrient transporters (e.g., sugar and ammonium) reflect specialization for host exploitation over broad soil nutrient scavenging.^[12]

Species

The genus Coccidioides comprises two primary pathogenic species: C. immitis, the type species primarily endemic to California, and C. posadasii, which is distributed across the southwestern United States (excluding central California) and northern Mexico.^[13] These species were distinguished based on phylogenetic analyses of single nucleotide polymorphisms (SNPs), gene sequences, and microsatellites, revealing C. posadasii as a monophyletic, genetically recombining clade divergent from C. immitis.^[13] Comparative genomic studies indicate a median nucleotide sequence identity of 98.3% between the two species, corresponding to approximately 1.7% divergence in nonrepetitive regions. Differentiation between C. immitis and C. posadasii relies on multilocus sequence typing (MLST) using 7–8 housekeeping genes (such as fragments of 450–500 bp) to assess allelic profiles and genetic variation, as well as amplified fragment length polymorphism (AFLP) analysis to evaluate population structure and low gene flow.^[14] SNPs in housekeeping genes serve as key diagnostic markers for species identification, enabling precise genotyping through phylogenetic clustering and detection of sequence variations that confirm the genetic boundaries between the species.^[14] Phenotypic distinctions include slower growth of C. posadasii on high-salt media compared to C. immitis.^[13]

Morphology and Life Cycle

Saprobic Phase

The saprobic phase of Coccidioides represents its free-living environmental form, where the fungus grows as mycelia in arid and semi-arid soils, particularly in alkaline desert regions with low organic content. In this stage, it develops extensive networks of septate hyphae that branch and elongate, adapting to nutrient-scarce conditions typical of the southwestern United States, northern Mexico, and parts of Central and South America.^[15]^[16] These hyphae mature and fragment asexually into barrel-shaped arthroconidia, the infectious propagules that serve as the primary means of dispersal. Arthroconidia measure approximately 2–4 μm in width and 3–6 μm in length, making them lightweight and easily aerosolized by wind or soil disturbance. Formation of arthroconidia occurs under favorable conditions, including warm temperatures of 25–30°C and low soil moisture, which promote hyphal segmentation and spore release while inhibiting excessive vegetative growth.^[15]^[17]^[16] Reproduction in the saprobic phase is exclusively asexual via arthroconidia production, with no sexual structures observed in natural settings. However, genomic studies have identified mating-type loci (MAT1-1 and MAT1-2) in balanced ratios across isolates, providing genetic evidence for cryptic sexual recombination and potential teleomorphs. Laboratory attempts to induce mating have been rare and largely unsuccessful, underscoring the predominantly clonal nature of propagation in the environment.^[18]^[19]

Parasitic Phase

Upon inhalation into the mammalian respiratory tract, arthroconidia of Coccidioides undergo dimorphic switching to the parasitic phase, developing into large, multinucleate spherules within 8–24 hours.^[17] This transformation is triggered primarily by the host's physiological conditions, including a temperature of 37°C and elevated CO₂ levels (10–20%), which mimic the lung environment and induce isotropic growth from the initial arthroconidium.^[17] In vivo, these spherules mature to diameters of 30–80 μm, featuring a thick, double-layered cell wall and internal segmentation that partitions the cytoplasm into compartments for endospore formation.^[20] As spherules enlarge, they fill with 100–300 endospores, each measuring 2–5 μm in diameter, through successive rounds of endosporulation that begin around 48 hours post-infection.^[21] Upon maturation, typically by 96–120 hours, the spherule ruptures, releasing viable endospores into surrounding tissues, which can then differentiate into new spherules and propagate the infection locally or via hematogenous dissemination.^[15] This endospore-releasing cycle sustains the parasitic form within the host, though completion of the full life cycle—wherein endospores revert to mycelial growth upon return to soil—is rarely observed in natural settings.^[15] In vitro models replicate this parasitic phase by culturing arthroconidia in specialized media, such as Converse medium supplemented with surfactants like Tamol SN, at 37°C and 10–20% CO₂ to promote spherule development and endosporulation for experimental study.^[17] These systems confirm the role of temperature and CO₂ as key environmental cues for dimorphic switching, enabling researchers to dissect the morphological and genetic changes without relying on animal models.^[17]

Ecology and Habitat

Environmental Distribution

_Coccidioides species are primarily endemic to arid and semiarid regions of the Western Hemisphere, with the highest concentrations in the southwestern United States, including California's San Joaquin Valley, Arizona, Texas, New Mexico, and Utah.^[22] These fungi also occur in northern Mexico, particularly in the states of Sonora and Baja California, as well as in parts of Central and South America, such as Argentina.^[2]^[3] The organism thrives in association with alkaline, sandy soils found in low-altitude desert environments characterized by less than 500 mm of annual rainfall and hot summers.^[23] These habitats typically feature sparse xerophytic vegetation and elevated average temperatures, which support the fungus's saprobic growth in the soil.^[2] Recent observations indicate an expansion of Coccidioides beyond traditional endemic zones, including detections in non-endemic U.S. states like Washington, attributed to climate change-induced shifts in temperature and precipitation patterns, alongside natural dispersal mechanisms such as wind and human activity.^[24]^[25] Soil serves as the primary reservoir for Coccidioides, with the fungus identified through environmental sampling techniques that reveal arthroconidia and mycelial forms embedded in desert soils.^[26] Concentrations of viable spores are often highest following rainy seasons, when soil moisture promotes mycelial proliferation, or during dust storms that aerosolize propagules from disturbed reservoirs.^[26]^[2]

Growth Conditions

_Coccidioides species thrive in alkaline soils with a pH range of 7 to 8, which supports mycelial growth and sporulation in their saprobic phase.^[23] These fungi exhibit optimal proliferation at temperatures between 25°C and 37°C, aligning with the warm conditions of their endemic arid environments. Low humidity levels, typically below 50% in soil, further favor their survival by limiting competition from moisture-dependent microbes, while the fungus persists in rodent burrows where organic matter accumulation provides a protected, nutrient-rich microhabitat.^[27] Nutritionally, Coccidioides is keratinophilic, deriving essential nitrogen and carbon from keratin in animal remains, as well as decaying vegetation within soil.^[28] Growth is inhibited by excessive soil moisture, which disrupts hyphal development.^[29] These constraints underscore the fungus's adaptation to semi-arid conditions with minimal water availability. Sporulation is triggered by environmental cycles of drought followed by brief rainfall events, promoting initial hyphal growth during wet phases and subsequent arthroconidia fragmentation and aerial dispersal as soils dry.^[30] This "grow and blow" dynamic enhances the release of infectious propagules into the air, particularly in dust-prone habitats.00202-9/fulltext)

Pathogenesis

Infection Process

Infection with Coccidioides species typically begins with the inhalation of airborne arthroconidia, the infectious propagules measuring 2–5 μm in size, which are released from soil-dwelling mycelia in arid environments. As few as 1–10 arthroconidia are sufficient to initiate infection in susceptible hosts, with these particles depositing primarily in the terminal bronchioles and alveoli of the lungs following inhalation.^[17] Upon deposition, the arthroconidia are rapidly phagocytosed by alveolar macrophages, but the fungus resists killing within these cells, initiating a dimorphic transition triggered by the host's body temperature (37°C) and elevated CO₂ levels (5–10%). This process begins within 8–24 hours post-inhalation, leading to the swelling and remodeling of arthroconidia into immature spherules by 48 hours.^[1]^[15] Spherule formation continues over the next 48–72 hours, with the structures enlarging to 60–100 μm in diameter by 96–120 hours, during which they evade innate immune responses through their thick, multilayered cell walls that resist further phagocytosis and enzymatic degradation.^[17] Inside the maturing spherules, internal septation occurs, culminating in the production of 200–300 endospores (2–4 μm each) that fill the structure. These endospores represent the next propagative phase, allowing the fungus to amplify locally within the pulmonary tissue. The spherules eventually rupture around 120–132 hours, releasing endospores that can infect adjacent cells or be taken up by additional macrophages, perpetuating the cycle and potentially leading to hematogenous or lymphatic dissemination to extrapulmonary sites such as the skin, bones, or central nervous system in a subset of cases.^[31]^[1] The dose-response relationship plays a critical role in infection outcomes, where low inocula (1–100 arthroconidia) often result in subclinical or asymptomatic primary infections in approximately 60% of immunocompetent individuals, reflecting effective containment by the host immune system.^[17] Higher inoculum exposures, such as those encountered during soil-disturbing activities like construction or archeological digs, increase the likelihood of symptomatic disease, though the risk of dissemination remains low (less than 5%) even in these scenarios and is primarily influenced by host factors rather than dose alone.^[31]^[15]

Virulence Factors

The virulence of Coccidioides species, including C. immitis and C. posadasii, relies on several molecular and cellular factors that facilitate host invasion, immune evasion, and survival within the mammalian respiratory tract. These factors enable the fungus to transition from the saprobic arthroconidial phase to the parasitic spherule phase, where it differentiates into large, multinucleate structures that release endospores for dissemination. Key among these are surface glycoproteins, enzymes involved in environmental modulation, and antioxidants that counteract host defenses. A prominent virulence factor is the spherule outer wall glycoprotein (SOWgp), a parasitic-phase-specific adhesin expressed on the surface of maturing spherules. SOWgp binds to host extracellular matrix components such as laminin, vitronectin, and fibronectin, as well as to type II alveolar cells, promoting fungal attachment and initial colonization of lung tissue.^[32] Knockout studies demonstrate that disruption of the SOWgp gene reduces adhesion to host cells and attenuates virulence in murine models, with mutants showing decreased fungal burden and prolonged host survival.^[32] Additionally, SOWgp contributes to immune evasion by inducing a nonprotective Th2-biased immune response, misdirecting T-cell differentiation away from the protective Th1 pathway and enhancing antibody production against repetitive epitopes that do not confer sterilizing immunity.^[33] This immunomodulatory role is supported by the protein's tandem repeats, which evolve through concerted mechanisms like unequal crossing-over, allowing antigenic variation to persist during infection.^[33] Urease, encoded by a single gene in Coccidioides, plays a critical role in virulence by hydrolyzing urea into ammonia and carbon dioxide, thereby modulating the pH of the infection microenvironment and acquiring nitrogen nutrients. Infected lung tissues exhibit elevated pH (up to 7.7), which urease exacerbates through ammonia release, promoting tissue damage and fungal survival in alkaline conditions.^[34] Nutrient acquisition is facilitated as the parental strain rapidly consumes exogenous urea (from 10 mM to 4.2 mM over 7 days in vitro), while urease-deficient mutants show minimal uptake and reduced ammonia production.^[34] Gene disruption experiments confirm urease's importance, as mutants induce less inflammation, form smaller lesions, and yield 55% mouse survival compared to 0% with wild-type strains.^[34] This pH elevation also aids in phagosomal neutralization, enhancing intracellular persistence during early infection stages.^[35] Genomic analyses reveal that Coccidioides genomes, approximately 28-29 Mb in size, encode around 8,000-9,000 protein-coding genes, including a repertoire of secreted effectors that support virulence.^[36] Notable among these are chitinases (e.g., CTS2 and CTS3), which are upregulated in the spherule phase and facilitate cell wall remodeling during endosporulation and tissue invasion.^[37] Disruption of these chitinase genes attenuates fungal replication and infectivity, as seen in vaccine strains unable to complete asexual reproduction.^[38] Transcriptomic studies further identify over 40% of putative secreted effectors as proteases, suggesting a strategy for degrading host barriers and evading innate immunity.^[39] Resistance to oxidative stress is another essential virulence attribute, mediated primarily by superoxide dismutases (SODs) such as SOD1 and SOD3, which are upregulated during spherule maturation to detoxify reactive oxygen species from host phagocytes.^[40] These enzymes enable survival against the oxidative burst in alveolar macrophages, with SOD3's secretion enhancing extracellular protection.^[40] Comparative genomics between C. immitis and C. posadasii highlight minor variations in gene content and repetitive elements (e.g., 17% vs. 12% repetitive DNA), but no definitive species-specific differences in virulence potential have been established, though C. posadasii's greater genetic diversity may influence adaptation.^[41]

Clinical Manifestations

Primary Infection

Primary infection with Coccidioides species typically occurs following inhalation of arthroconidia from soil in endemic areas, resulting in an initial pulmonary response known as acute coccidioidomycosis or Valley fever. Approximately 60% of infections remain asymptomatic, with no clinical manifestations despite infection.^[42] In the remaining 40% of cases that are symptomatic, the incubation period ranges from 1 to 3 weeks post-exposure.^[31] Symptomatic primary infection presents as a self-limited flu-like illness characterized by fever, dry cough, fatigue, headache, myalgias, and arthralgias.^[43] These symptoms generally last 1 to 3 weeks and resolve spontaneously in immunocompetent hosts without specific antifungal therapy.^[44] Common extrapulmonary signs include erythema nodosum or erythema multiforme, which appear in 20% to 30% of symptomatic cases as tender, red nodules on the shins or target-like lesions, respectively; these hypersensitivity reactions signal effective cell-mediated immunity and typically resolve without intervention.^[45] Chest radiographs in symptomatic patients often show focal or multifocal infiltrates, nodules, or consolidation, predominantly involving the lower lung lobes, sometimes accompanied by hilar lymphadenopathy.^[46] Serologic testing reveals IgM antibody detection in about 50% of cases within the first week, rising to 70% to 90% by 3 weeks, confirming recent exposure and aiding diagnosis.^[47] In immunocompetent individuals, primary infection rarely progresses beyond the lungs.

Disseminated Disease

Disseminated coccidioidomycosis occurs when the fungal infection spreads beyond the primary pulmonary site, affecting extrapulmonary organs and leading to severe, potentially life-threatening complications. This form develops in less than 1% of immunocompetent individuals following primary infection.^[48] In contrast, dissemination affects 30%–50% of immunosuppressed hosts, such as patients with HIV/AIDS, organ transplants, or those receiving immunosuppressive therapies.^[49] The most frequent sites of dissemination are the meninges (in 20%–50% of cases), bones and skin (each in approximately 20%), and chronic pulmonary structures.^[50]^[51] Meningeal involvement typically manifests as chronic headache and may progress to hydrocephalus due to basilar inflammation and adhesions.^[52] Skeletal dissemination presents as osteomyelitis, often with lytic bone lesions that can cause pain, swelling, and structural damage, particularly in the spine or long bones.^[53] Chronic pulmonary involvement includes fibrocavitary disease, leading to persistent cavities and fibrosis that impair lung function over time.^[54] Untreated disseminated disease is usually fatal (mortality approaching 100% in cases involving the meninges).^[55]^[56] Certain host factors increase the risk of progression from primary infection to dissemination, including African American or Filipino ethnicity, pregnancy (particularly in the third trimester), and diabetes mellitus.^[49]^[57] These risks highlight the importance of monitoring high-risk groups for early signs of spread.

Epidemiology

Endemic Areas

Coccidioides species, the fungi responsible for coccidioidomycosis (also known as Valley fever), are primarily endemic to arid and semiarid regions of the Western Hemisphere, with the core zones concentrated in the southwestern United States and northern Mexico. In the United States, the majority of cases occur in Arizona, which accounts for approximately 64.5% of reported infections, followed by California with about 32.5%, based on surveillance data from 2011 to 2017. These states, along with smaller foci in Nevada, New Mexico, Utah, and Texas, feature alkaline soils with low organic matter where the fungus thrives in undisturbed desert environments.^[58]^[22]^[59] Emerging endemicity has been observed in previously non-endemic areas due to climate shifts in the 2020s, including increased temperatures and altered precipitation patterns that favor fungal dispersal. In the Pacific Northwest, cases have surfaced in south-central Washington, linked to local soil contamination possibly exacerbated by dust storms and wildfires, while predictive models indicate potential expansion into southern Idaho and other northern drylands by mid-century. These changes highlight how warming climates may redistribute Coccidioides beyond traditional boundaries, with initial detections tied to environmental disturbances.^[24]^[60]^[22] Globally, endemic foci extend to scattered regions in South America, including Patagonia in Argentina and certain areas of Colombia, where soil conditions support sporadic outbreaks among human and animal populations. Non-endemic regions like Europe see primarily travel-related imported cases, with reports in 2025 documenting laboratory-confirmed infections in countries such as Bulgaria among individuals returning from endemic zones. These extensions underscore the fungus's adaptation to semi-arid habitats worldwide, though transmission outside the Americas remains rare and importation-driven. A 2025 systematic review identified 39 travel-related and 98 migration-associated infections across Europe from 1948 to 2022.^[59]^[61]^[62] Endemic areas are delineated through comprehensive soil surveys and studies of animal reservoirs, which reveal the fungus's presence in undisturbed soils and its association with burrowing mammals. Surveys across the southwestern U.S. have identified Coccidioides in up to 37% of rodent burrow samples from natural sites, using molecular detection methods to map habitat suitability based on soil pH, texture, and moisture. Animals such as coyotes and rodents serve as indicators and potential disseminators, with infection rates in wild populations correlating to high-risk zones and aiding in predictive modeling of exposure areas.^[63]^[18]^[64]

Incidence and Trends

In the United States, approximately 20,000–23,000 cases of coccidioidomycosis are reported annually to the CDC, primarily from endemic regions in the southwestern states, with 22,939 cases in 2024.^[6] This figure represents a substantial increase from earlier decades; for instance, national reported cases rose from around 2,300 in 1998 to over 21,000 by 2023, reflecting an approximately 800% growth driven by factors such as increased construction activities, dust exposure from land development, and climate variability that enhances fungal spore dispersal. Provisional data for 2025 indicate continued high incidence, with California reporting over 6,700 cases by mid-year and Arizona seeing seasonal peaks. In Arizona, a key endemic area, case incidence often peaks in late summer and fall following the monsoon season (July–September), when heavy rains promote fungal growth in soil, followed by dry winds that aerosolize arthroconidia.^[7]^[65]^[6] Demographic patterns highlight vulnerable populations, with incidence rates highest among older adults; individuals over 65 years face roughly twice the risk of severe disease compared to younger groups, owing to age-related immune decline.^[66] Males, particularly those in outdoor occupations like construction, agriculture, and military service, experience elevated exposure and report higher case rates due to frequent dust inhalation.^[67] Ethnic disparities are notable, as people of Filipino ancestry have a 10-fold increased risk of disseminated disease relative to non-Hispanic whites, a pattern linked to genetic factors influencing immune response to the fungus.^[68] Globally, coccidioidomycosis remains largely confined to the Americas, but imported cases are rising in non-endemic regions like Europe due to international travel and migration. Climate models project further epidemiological shifts, with northward expansion of the fungus's suitable habitat in the U.S. by 2050 under moderate warming scenarios, potentially into states like Idaho and Wyoming, which could amplify incidence through extended arid-dry cycles favoring spore release.^[69]

Diagnosis

Serological Tests

Serological tests for Coccidioides infection primarily detect antibodies produced in response to exposure, aiding in the diagnosis of coccidioidomycosis, particularly in endemic areas where clinical suspicion is high.^[67] These assays target immunoglobulin M (IgM) and immunoglobulin G (IgG) antibodies, with IgM indicating acute or recent infection and IgG reflecting past or ongoing exposure.^[70] Common methods include enzyme immunoassay (EIA) for initial screening and immunodiffusion (ID) for confirmation, often followed by complement fixation (CF) to assess disease severity.^[71] Enzyme immunoassay detects IgM and IgG antibodies, with sensitivities ranging from 35% to 61% for IgM and 53% to 69% for IgG in various kits, and specificities of 70% to 100% across commercial assays like those from Meridian Bioscience and IMMY.^[72] Immunodiffusion provides higher specificity, exceeding 95%, and is used to confirm positive EIA results by identifying precipitin bands for IgM (early response) or IgG (later response), with overall sensitivity around 60% but greater reliability in non-acute settings.^[71] These tests are most effective when performed 1-3 weeks after symptom onset, as IgM antibodies peak during weeks 1-2 and decline after 3-6 months, while IgG rises shortly after and can persist for years, indicating resolved or chronic infection.^[70] Complement fixation quantifies IgG levels through serial dilutions, with titers greater than 1:16 often signaling dissemination or severe disease, such as extrapulmonary involvement, though titers can remain elevated post-recovery.^[73] CF sensitivity ranges from 65% to 83%, with high specificity, but it is less useful early in infection due to delayed antibody development.^[71] False-negative results occur in up to 20-30% of cases, particularly in early infection before seroconversion or in immunosuppressed patients who mount weaker immune responses.^[74] Antigen detection assays, such as the Coccidioides antigen enzyme immunoassay (EIA) on serum, urine, or other fluids, provide rapid results and aid diagnosis, particularly in disseminated or immunocompromised cases. These tests detect fungal cell wall antigens with overall sensitivity of approximately 73% and specificity greater than 90%, though sensitivity is higher (up to 90%) in severe disseminated disease and lower (around 50%) in uncomplicated pulmonary cases; cross-reactivity with other fungi can occur.^[75]^[76] Standardization of serological tests is supported by the Centers for Disease Control and Prevention (CDC), which collaborates with reference laboratories and study groups to evaluate commercial assays and reduce interlaboratory variability, ensuring consistent interpretation across clinical settings.^[72] Positive serology in symptomatic patients from endemic regions typically suffices for diagnosis, though confirmation via culture may be pursued in ambiguous cases.^[67]

Culture and Molecular Methods

Cultivation of Coccidioides species involves inoculating clinical specimens onto standard fungal media such as Sabouraud dextrose agar or blood agar, with incubation at 25–30°C yielding initial mycelial colonies in 2–3 days and mature arthroconidia formation within 1–2 weeks.^[77] Cycloheximide-supplemented media can be used selectively to inhibit contaminating saprobic fungi while supporting Coccidioides growth.^[77] Due to the aerosolization risk of highly infectious arthroconidia produced in the mycelial phase, all manipulation of sporulating cultures requires biosafety level 3 (BSL-3) facilities and practices to prevent laboratory-acquired infections.^[3] In vivo, arthroconidia convert to the tissue-invasive spherule phase at mammalian body temperatures (37–40°C), a dimorphic shift that can be replicated in animal models or specialized liquid media like Converse medium for research purposes.^[3] Molecular methods for Coccidioides detection primarily utilize real-time polymerase chain reaction (PCR) assays targeting the internal transcribed spacer 1 (ITS1) region of ribosomal DNA or genus-specific genes such as proline-rich antigen 2 (RRA2), enabling direct identification from clinical specimens like tissue, bronchoalveolar lavage fluid, or cerebrospinal fluid.^[78] These assays exhibit high analytical sensitivity, with limits of detection as low as 1 fg of genomic DNA (equivalent to approximately 10 genome copies per reaction), and clinical sensitivities of 80–100% in samples with sufficient fungal burden, outperforming culture in speed and from antifungal-treated patients.^[78]^[79] Species differentiation between C. immitis and C. posadasii—the two primary pathogens—is achieved via single nucleotide polymorphisms (SNPs) or an 86-bp deletion in targeted amplicons, using probe-based or sequencing approaches integrated into the real-time PCR workflow.^[79] Histopathological analysis of tissue biopsies provides direct visualization of Coccidioides spherules, which are pathognomonic large structures (20–80 μm) filled with endospores (2–5 μm), confirming infection through examination of affected organs like skin, lung, or meninges, particularly in disseminated cases where spherules are more abundant.^[47] These forms are best highlighted by fungal-specific stains such as Gomori methenamine silver (GMS) or periodic acid-Schiff (PAS), which stain the thick double-walled spherule capsules and internal endospores distinctly against surrounding granulomatous inflammation; hematoxylin and eosin (H&E) staining suffices for initial screening but may require silver enhancement for subtle cases.^[77] Biopsy confirmation is particularly valuable in immunocompromised patients with extrapulmonary dissemination, where spherules are more abundant and diagnostic yield is enhanced by targeting suspicious lesions.^[47]

Treatment and Management

Pharmacological Therapy

The pharmacological therapy for coccidioidomycosis relies on antifungal agents, with azoles serving as first-line treatment for most cases due to their oral bioavailability and efficacy against Coccidioides species.^[80] For mild primary pulmonary infections, particularly in patients with symptoms lasting more than a few weeks or those at higher risk such as the elderly or immunocompromised, oral azoles are recommended. Fluconazole at a dose of 400 mg daily or itraconazole at 200 mg twice daily is typically administered for 3 to 6 months, achieving response rates of 80% to 90% in compliant immunocompetent patients.^[81]^[1] These regimens promote resolution of symptoms like fever, cough, and fatigue while minimizing dissemination risk.^[82] In severe or disseminated disease, including diffuse pneumonia, bone/joint involvement, or meningitis, initial induction therapy involves intravenous lipid formulation of amphotericin B at 3 to 5 mg/kg daily to rapidly control infection, followed by transition to oral azole maintenance.^[80] Fluconazole remains the preferred maintenance agent at 400 to 800 mg daily, with durations extending to at least 1 year for non-central nervous system dissemination and lifelong for coccidioidal meningitis to prevent relapse.^[1] Itraconazole at 200 mg twice daily serves as an alternative for bone and joint disease, though its absorption requires monitoring.^[81] For azole-resistant strains or treatment failures, voriconazole (200 to 400 mg twice daily) is considered an effective alternative, particularly in immunocompromised hosts.^[83] Therapeutic monitoring is essential to ensure efficacy and safety, including measurement of serum antifungal drug levels for itraconazole (target trough >1 mcg/mL) and regular assessment of liver function tests due to potential hepatotoxicity.^[80] Serial serologic testing, such as complement fixation titers, guides response evaluation, with a decline indicating improvement.^[81] Updated 2025 care guidelines emphasize initiating early antifungal therapy in high-risk groups, including those with diabetes, organ transplants, or ethnic predispositions (e.g., African American or Filipino descent), to reduce progression to disseminated forms.^[81]^[84]

Surgical Interventions

Surgical interventions for coccidioidomycosis are typically reserved for complications that do not respond adequately to antifungal therapy alone, particularly in cases of localized or structural disease involving the pericardium, spine, central nervous system, or lungs. These procedures aim to alleviate symptoms, remove infected tissue, or manage mechanical complications such as effusions, instability, or obstructions.^[80] Drainage of pericardial effusion is indicated in severe coccidioidal pericarditis, where accumulation of fluid leads to tamponade or hemodynamic compromise. Pericardiocentesis or surgical pericardial window provides symptomatic relief and facilitates diagnostic sampling, preventing further cardiac compression in affected patients.^[85] For vertebral osteomyelitis, surgical debridement is recommended when there is spinal instability, cord or nerve root compression, or large paraspinal abscesses unresponsive to medical management. Approaches may include anterior, posterior, or lateral access, often combined with stabilization via fusion or instrumentation to restore structural integrity and reduce neurological deficits. Success rates improve to approximately 86% when surgery is paired with antifungal therapy, compared to 58% with antifungals alone.^[80]^[86] In coccidioidal meningitis complicated by hydrocephalus, ventriculoperitoneal (VP) shunting is the standard intervention for managing increased intracranial pressure and ventriculomegaly due to arachnoid scarring or basal cistern obliteration. This procedure diverts cerebrospinal fluid to prevent progression to coma or death, often requiring multiple revisions, with shunt failure rates of approximately 50% and an average of 2.5 revisions per affected case.^[80]^[87] Lung resection is considered for chronic fibrocavitary disease, occurring in 5-10% of pulmonary cases, particularly when cavities persist beyond two years, cause hemoptysis, or recur despite antifungal treatment. Procedures such as lobectomy or segmentectomy, often via video-assisted thoracoscopic surgery (VATS), achieve success rates of 70-85% when combined with adjunct antifungals, with low recurrence in experienced centers. These interventions complement the primary antifungal backbone by addressing persistent structural lesions.^[80]^[88]^[89] Emerging minimally invasive techniques, such as CT-guided biopsy or aspiration, are increasingly used for diagnostic confirmation and targeted drainage in accessible lesions like vertebral abscesses or pulmonary nodules, reducing the need for open surgery. Postoperative recurrence rates following these approaches hover around 20%, emphasizing the importance of long-term antifungal follow-up to mitigate relapse.^[80]^[90]^[91]

Prevention and Control

Environmental Measures

Environmental measures for controlling Coccidioides exposure focus on mitigating the dispersal of fungal spores from soil in endemic areas, primarily through dust suppression and regulatory oversight. In construction and land disturbance activities, soil remediation strategies include wetting the ground with water trucks to prevent airborne particles, covering soil piles with tarps, and applying dust stabilizers or promoting vegetation growth to stabilize surfaces.^[92]^[93] These approaches have been recommended following outbreaks linked to site development, such as solar farm projects where inadequate dust control led to increased cases among workers.^[94] Surveillance efforts are essential for early detection and response, with coccidioidomycosis designated as a nationally notifiable disease by the CDC, requiring reporting of cases to track incidence and guide interventions.^[95] Environmental sampling, particularly air monitoring after dust storms, helps identify spore presence; for instance, studies in Phoenix, Arizona, have detected Coccidioides DNA in air filters collected post-storm, informing public health alerts.^[96] While rodents serve as natural hosts that may disturb soil and release spores from burrows, targeted vector control remains limited due to challenges in detecting infected animals.^[97]^[98] U.S. policy frameworks emphasize risk reduction in high-risk activities like archaeology and construction through guidelines from agencies such as OSHA and the USGS. These include mandatory dust control plans for fieldwork in endemic zones, such as limiting ground disturbance and using stabilizers during excavations.^[92]^[99] The CDC highlights archaeology as an occupational risk factor and promotes site-specific measures to curb exposure in arid regions.^[67]

Personal Protective Strategies

Individuals engaging in outdoor activities in endemic areas for Coccidioides, such as construction, excavation, or gardening, should prioritize avoiding dust exposure to minimize inhalation of infectious arthroconidia. In dusty conditions, particularly during dry seasons when winds disperse soil particles, refraining from soil-disturbing tasks like digging is advised, as these periods heighten aerosolization risks. If avoidance is not feasible, wearing a properly fitted N95 respirator is recommended to filter airborne particles effectively, reducing exposure in high-dust environments like construction sites.^[100]^[101] For high-risk populations, including pregnant individuals and those who are immunocompromised (e.g., due to HIV, organ transplantation, or corticosteroid use), stricter precautions are essential given their elevated likelihood of severe or disseminated disease. These groups should consult healthcare providers about avoiding non-essential travel to hotspots in the southwestern United States and limiting participation in soil-disrupting activities altogether.^[67]^[102] In cases of known exposure, such as laboratory accidents involving Coccidioides cultures, post-exposure prophylaxis with oral azoles like fluconazole (400 mg daily) or itraconazole (200 mg twice daily) for 6 weeks may be considered for non-pregnant, exposed individuals to prevent primary infection, though evidence is limited and decisions should involve infectious disease specialists. Immediate decontamination, such as washing skin with soap and water, is also advised following potential contact.^[103]^[104] Public education plays a key role in personal prevention, with awareness campaigns in Arizona promoting recognition of risks and adoption of protective behaviors among residents and workers. These initiatives, supported by state health departments and centers like the Valley Fever Center for Excellence, have enhanced community knowledge and encouraged proactive measures to curb infections.^[105]^[106]

Vaccine Development

No licensed vaccine exists for coccidioidomycosis as of November 2025, but research has advanced a live attenuated candidate toward Phase 1 clinical trials, supported by the National Institutes of Health. This development aims to provide long-term protection for at-risk populations in endemic regions, building on preclinical studies demonstrating efficacy in animal models.^[107]^[108]

History

Discovery and Early Research

The first description of what is now known as coccidioidomycosis occurred in 1892, when Argentine medical student Alejandro Posadas and Roberto Wernicke observed skin lesions in a 32-year-old soldier in Buenos Aires, initially mistaking the causative agent for a protozoan resembling coccidia due to the observed spherule-like structures in tissue samples.^[109]^[68] Posadas's and Wernicke's case report marked the initial recognition of the disease, though its fungal etiology remained unrecognized at the time.^[110] In 1896, American physicians Thomas Caspar Gilchrist and Emmet Rixford reported a similar case in a farm worker in San Francisco, California, naming the organism Coccidioides immitis based on its resemblance to coccidian protozoa and the severe clinical course observed.^[110] This naming stemmed from a U.S. patient with disseminated lesions, providing the first detailed pathological description outside Argentina.^[109] Four years later, in 1900, William Ophüls and Herbert C. Moffitt at Cooper Medical College (now Stanford) confirmed the fungal nature of C. immitis by successfully culturing the organism from a patient's lung tissue, revealing its dimorphic characteristics with a mold phase in vitro and spherules in vivo.^[110] Their work, including animal inoculation experiments, definitively shifted classification from protozoan to fungus and highlighted the pulmonary primary site of infection.^[111] During the mid-20th century, particularly from the 1930s to 1950s, researchers elucidated the full life cycle of Coccidioides, establishing its dimorphic nature and environmental reservoir. In 1932, R. A. Stewart and Kenneth F. Meyer isolated the fungus from San Joaquin Valley soil samples, linking it directly to environmental exposure through guinea pig inoculations and demonstrating its saprobic growth in alkaline desert soils.^[112]^[113] Building on this, Charles E. Smith and colleagues at Stanford University conducted extensive field studies in the 1940s, identifying arthroconidia as the airborne infectious propagules produced in the mycelial soil phase, which transform into tissue spherules upon inhalation, thus completing the cycle from saprophyte to parasite.^[109] These findings, driven by increased cases during Dust Bowl migrations and World War II military training in endemic areas, provided critical insights into transmission dynamics.^[109] A major taxonomic advancement came in 2002, when Matthew C. Fisher and colleagues used multilocus DNA sequencing to distinguish a second species, Coccidioides posadasii, from C. immitis, based on genetic divergence among non-California isolates from Texas, Arizona, and Latin America. This split, supported by phenotypic differences like slower growth on high-salt media, honored Posadas's original discovery and clarified geographic speciation without altering the shared life cycle or clinical presentation.^[114]

Etymology

The genus name Coccidioides derives from the Greek words kokkis (κόκκος), meaning "berry" or "little berry," and eidos (εἶδος), meaning "form" or "resemblance," reflecting the spherical, berry-like appearance of the organism's spherules that initially resembled those of the protozoan group Coccidia.^[110] This nomenclature was coined in 1896 by American physicians T. Caspar Gilchrist and Emmet Rixford, who classified the pathogen among the Sporozoa based on its morphological similarity to coccidian parasites.^[115]^[110] The species epithet immitis comes from the Latin word meaning "harsh" or "unyielding," chosen to describe the severe and aggressive clinical course of the disease it causes.^[110] In contrast, Coccidioides posadasii was formally described as a distinct species in 2002, with its epithet honoring Alejandro Posadas, the Argentine medical student who first reported a case of coccidioidomycosis in 1892 and contributed to its early recognition.^[114] This taxonomic split distinguished non-California populations from C. immitis, which is primarily associated with California's San Joaquin Valley.^[114] The early nomenclature of Coccidioides was heavily influenced by initial misclassification as a coccidian parasite, stemming from the discovery of large, double-contoured spherules in tissue samples that mimicked protozoan structures, leading researchers like Gilchrist to place it within the Sporozoa subclass before its fungal nature was confirmed in the early 1900s.^[115]^[116] This confusion delayed accurate identification but underscored the pathogen's unique dimorphic life cycle, which alternates between tissue spherules and environmental mycelia.^[115]

References

[1]
Coccidioidomycosis - StatPearls - NCBI Bookshelf - NIH
Coccidioides is a genus of dimorphic fungi that exist as mycelia or as spherules (1). Both mycelia and spherules are asexual forms. The sexual form of ...
[2]
The mysterious desert dwellers: Coccidioides immitis and ...
The genus Coccidioides consists of two species: C. immitis and C. posadasii. Prior to 2000, all disease was thought to be caused by a single species, ...
[3]
Coccidioides Species: A Review of Basic Research: 2022 - PMC
Aug 16, 2022 · Coccidioides immitis and posadasii are closely related fungal species that cause coccidioidomycosis. These dimorphic organisms cause disease in immunocompetent ...
[4]
Coccidioides immitis - Mycobank
Classification. Fungi > Dikarya > Ascomycota ... Taxonomic and diagnostic markers for identification of Coccidioides immitis and Coccidioides posadasii.
[5]
Taxon: Coccidioides immitis - USDA
Taxonomic Authority: Mycobank. Notes: Taxonomic Classification Level. Kingdom: Phylum: Class: Order: Fungi; Ascomycota; Eurotiomycetes; Onygenales. Family: ...Missing: hierarchy | Show results with:hierarchy
[6]
Coccidioidomycosis: epidemiology - PMC - PubMed Central - NIH
Consequently, in 1896, it was given the name Coccidioides (derived from its morphologic appearance of “resembling Coccidia”) immitis (“not mild”, because it was ...
[7]
Local Population Structure and Patterns of Western Hemisphere ...
Divergence time analysis. To estimate evolutionary rates for all of the Coccidioides species, as well as divergence times for C. immitis and C. posadasii ...
[8]
Genome analysis reveals evolutionary mechanisms of adaptation in ...
Mar 14, 2018 · ... Coccidioides in the family Onygenaceae. Here, we have sequenced four additional Onygenales species from the family Ajellomycetaceae; this ...
[9]
Molecular and phenotypic description of Coccidioides posadasii sp ...
Jan 31, 2017 · In this paper, we have used phylogenetic analyses of microsatellite loci to identify isolates as C. immitis or C. posadasii. This approach was ...
[10]
Molecular markers in the epidemiology and diagnosis of ... - Elsevier
Molecular markers have been used in the study of coccidioidomycosis to identify species, type isolates, determine the structure or reproductive mode and ...
[11]
Names Record - Species Fungorum
Record Details: Coccidioides rosea Bat., H. Maia, S.K. Shome & Oliveira [as 'roseum'], in Batista et al., Monit. Zool. Ital. 3(1): 71 (1963).
[12]
Coccidioidomycosis: Epidemiology, Fungal Pathogenesis, and ...
Jun 14, 2019 · Coccidioidomycosis can result from the inhalation of infectious spores of Coccidioides species (spp.) immitis or posadasii.Missing: rosea saprophytic
[13]
[PDF] Coccidioidomycosis - The Center for Food Security and Public Health
Sep 3, 2021 · Importance. Coccidioidomycosis is a fungal disease, almost always acquired from the environment, that can affect many species of mammals and ...
[14]
Early Events in Coccidioidomycosis - PMC - PubMed Central
Their life cycle progresses from a mycelial (saprobic/soil) phase to a spherule/endospore (parasitic/host) phase (2, 3). The two known species are Coccidioides ...
[15]
Recent Advances in Our Understanding of the Environmental ...
Genomic and population analyses of the mating type loci in Coccidioides species reveal evidence for sexual reproduction and gene acquisition. Eukaryot. Cell ...
[16]
Cryptic Speciation and Recombination in the Fungus ...
As is the case with many other hu- man pathogenic fungi, no sexual stage (teleomorph) has been reported. This fungus has shown extensive genetic variability ...
[17]
Cellular plasticity of pathogenic fungi during infection - PMC
Jun 4, 2020 · spherules, spherical, 30–80 μm in diameter, containing 100–300 endospores ... (C) The spherule-endospore cycle, unique to Coccidioides infections.White-To-Opaque And... · Table 1. The Variety Of... · Fig 1. Morphological...<|control11|><|separator|>
[18]
Epidemiologic, Clinical, and Diagnostic Aspects of ... - PubMed Central
The Coccidioides genus is considered dimorphic. Dimorphism is characterized by production of filamentous (mycelial) forms by certain fungi during their ...
[19]
Areas with Valley Fever - CDC
Apr 24, 2024 · Coccidioides lives in soil and dust in the Southwest and parts of the Pacific. Historically, Valley fever spreads in Arizona, California, Nevada and New Mexico.
[20]
The habitat of Coccidioides spp. and the role of animals as ...
Oct 10, 2016 · Coccidioides species not only infect humans but can also infect other mammals (land, aquatic, wild or domestic), reptiles and birds.
[21]
Expansion of Coccidioidomycosis Endemic Regions in the United ...
Aug 30, 2019 · Generally, the disease is limited to areas that are hot and dry. Climate change will cause the western United States to become hotter and may ...
[22]
Was Coccidioides a Pre-Columbian Hitchhiker to Southcentral ...
Mar 7, 2023 · THE WASHINGTON STATE COCCIDIOIDES ... Expansion of coccidioidomycosis endemic regions in the United States in response to climate change.
[23]
Environmental Detection of Coccidioides: Challenges and ... - MDPI
A previous investigation [101] states that Coccidioides necessitates specific soil conditions, including xerophytic plant communities and particular soil types ...
[24]
Coccidioides Niches and Habitat Parameters in the Southwestern ...
Oct 10, 2007 · Material classified as very fine sand and silt is abundant in all of the Coccidioides-bearing soils and may be their most common shared feature.Missing: alkaline | Show results with:alkaline
[25]
[PDF] Epidemiology and Pedagogy - eScholarship
While most soil fungi thrive in conditions that maintain a moisture rich soil environment, Coccidioides are typically found in arid environments with distinct ...
[26]
Relating coccidioidomycosis (valley fever) incidence to soil moisture ...
Mar 6, 2017 · The results indicate that in both states, coccidioidomycosis incidence is related to soil moisture levels from previous summers and falls.
[27]
Effects of precipitation, heat, and drought on incidence and ...
May 17, 2023 · Periods of precipitation are thought to facilitate Coccidioides hyphal growth and sporulation [11, 12], and hot and dry periods cause the ...
[28]
Coccidioidomycosis: A Contemporary Review - PMC
Mar 1, 2022 · Endemic areas of Coccidioides spp. in the US appear to be expanding. Studies have recently demonstrated that, in Nevada, cases are not only ...
[29]
A Parasitic Phase-Specific Adhesin of Coccidioides immitis ...
The parasitic cell surface glycoprotein encoded by the SOWgp gene appears to function as an adhesin and contributes to the virulence of C. immitis.
[30]
Concerted Evolution in the Repeats of an Immunomodulating Cell ...
SOWgp appears to contribute to the virulence of Coccidioides spp. both by functioning as an adhesin and by modulating the host's immune response (Hung et al.
[31]
Urease Produced by Coccidioides posadasii Contributes to the ...
We present evidence that urease activity is an important virulence determinant of Coccidioides during interaction of the pathogen with murine lung tissue.
[32]
Environmental pH modulation by pathogenic fungi as a strategy to ...
Feb 23, 2017 · The spherules of Coccidioides spp., causative agents of coccidioidomycosis, release enzymatically active urease and ammonia to raise the ...
[33]
Coccidioides posadasii - KEGG GENOME
Genome information ; Statistics, Number of nucleotides: 28193268. Number of protein genes: 8299. Number of RNA genes: 137 ; Created, 2010 ; Reference, PMID: ...
[34]
Defining Critical Genes During Spherule Remodeling and ... - Frontiers
Coccidioides immitis and C. posadasii are soil dwelling dimorphic fungi found in North and South America. Inhalation of aerosolized asexual conidia can ...Missing: habitation | Show results with:habitation
[35]
A Genetically Engineered Live Attenuated Vaccine of Coccidioides ...
Two chitinase genes (CTS2 and CTS3) were disrupted to yield the attenuated strain, which was unable to endosporulate and was no longer infectious. Vaccinated ...
[36]
Transcriptomic atlas throughout Coccidioides development reveals ...
Mature spherules rupture, releasing hundreds of internal cells known as endospores which can each go on to form another spherule in a cycle called spherulation.
[37]
Gene expression in human fungal pathogen Coccidioides immitis ...
May 28, 2013 · 22% of C. immitis genes were differentially expressed in either day 2 or day 8 spherules compared to mycelia, and about 12% of genes were ...
[38]
Comparative genomic analyses of the human fungal pathogens ...
Coccidioides is composed of two closely related species, Coccidioides immitis and Coccidioides posadasii, and is a member of the Onygenales, an order ...Missing: AFLP | Show results with:AFLP
[39]
Increase in Coccidioidomycosis --- California, 2000--2007 - CDC
Feb 13, 2009 · Of an estimated 150,000 new infections annually in the United States (2), approximately 60% are asymptomatic (1). Patients with symptoms ...
[40]
Coccidioidomycosis - Ohio Department of Health
Sep 17, 2024 · Symptomatic persons (40% of cases) usually present 1 to 3 weeks after exposure with fatigue, cough, dyspnea, headache, night sweats, myalgias, ...
[41]
Coccidioidomycosis (Valley Fever) - SanDiegoCounty.gov
Sep 19, 2024 · Symptoms of Valley Fever may appear between 1-3 weeks after a person breathes in the fungal spores. with symptoms usually lasting a few weeks to ...Missing: incubation period arthralgia
[42]
Coccidioidomycosis and the skin: a comprehensive review - PMC
It is estimated that 150,000 new infections occur annually in areas of the Southwestern United States. Coccidioidomycosis is not a nationally reportable disease ...
[43]
[PDF] The Clinician's Guide to Diagnosing Primary Pulmonary ...
A failure to improve after one or more courses of bacterial antibiotics or persistence of symptoms over weeks is strongly suggestive of coccidioidomycosis. ...
[44]
Coccidioidomycosis and Valley Fever Workup - Medscape Reference
Dec 16, 2022 · IgM is detected in approximately half of all coccidioidal infections within the first week and in approximately 90% by 3 weeks. The IgM antibody ...
[45]
Coccidioidomycosis | Red Book - AAP Publications
... (IDSA) clinical practice guideline for the treatment of coccidioidomycosis . ... Erythema nodosum in a preadolescent with primary pulmonary coccidioidomycosis.
[46]
Risk Factors for Disseminated Coccidioidomycosis, United States
Jan 11, 2017 · How the host responds to and contains coccidioidomycosis is unclear, but dissemination occurs in 30%–50% of immunosuppressed hosts.
[47]
Disseminated coccidioidomycosis with multifocal musculoskeletal ...
Less than one percent of cases lead to disseminated infection, with the most common sites being the bones, joints, meninges, and skin. Twenty to 50% of ...
[48]
Coccidioidomycosis Osteoarticular Dissemination - PMC
Skeletal coccidioidomycosis accounts for about half of disseminated infections, with the vertebral spine being the preferred site of dissemination.
[49]
Coccidioidal Meningitis | UC Davis Center for Valley Fever
The most common life-threatening complications of meningitis include hydrocephalus, CNS vasculitis, cerebral ischemia, infarction, vasospasm and hemorrhage.
[50]
Coccidioidomycosis (Valley Fever) Imaging - Medscape Reference
Oct 5, 2021 · In patients with osteomyelitis, bone radiographs may show lytic lesions, periosteal elevation, and bony destruction (see the image below.).
[51]
[PDF] Coccidioidomycosis - American Thoracic Society
The chronic form sometimes develops years after getting infected. Disseminated coccidioidomycosis, is the most severe form of the disease and occurs in about 1% ...
[52]
Coccidioidomycosis in Immunocompromised at a Non-Endemic ...
Jun 18, 2024 · Of 31 CM cases, 71% were male and 55% were disseminated. For 42% of patients, there was no evidence of having lived in or visited an endemic ...
[53]
Valley Fever | Infectious Diseases - UC Davis Health
Aug 20, 2025 · People who are older than 60, Black, or Filipino are most at risk. Diabetes. People with diabetes are at risk for all types of fungal infections ...
[54]
Surveillance for Coccidioidomycosis — United States, 2011–2017
Sep 20, 2019 · Most cases were reported from Arizona (61,480 [64.5%]) and California (30,979 [32.5%]). Fewer cases were reported from Nevada, New Mexico, and ...
[55]
Clinical Cases of Coccidioidomycosis in the Americas in the Period ...
In Mexico, Coccidioides infection is considered to be as prevalent as in the endemic regions of the USA, with an average of 1500 cases reported per year, ...
[56]
Was Coccidioides a Pre-Columbian Hitchhiker to Southcentral ...
Mar 7, 2023 · Intensified disease surveillance identified several more cases of coccidioidomycosis in the region that lacked any relevant travel history to ...<|control11|><|separator|>
[57]
A RARE CASE OF LABORATORY-CONFIRMED ...
Sep 15, 2025 · Coccidioidomycosis is a systemic fungal infection with no local distribution in Europe , associated with travelling to endemic regions of the ...
[58]
Using soil survey data to model potential Coccidioides soil habitat ...
Feb 19, 2021 · We developed a fuzzy system model to predict suitable soil habitats for Coccidioides across the western United States based on parametersMissing: coyotes rodents
[59]
Coccidioides undetected in soils from agricultural land and ... - OSTI
May 25, 2023 · Coccidioidomycosis is a typically respiratory fungal disease that, in the United States, occurs primarily in Arizona and California.<|control11|><|separator|>
[60]
Reported Cases of Valley Fever - CDC
Apr 24, 2024 · Death rates. On average, there were approximately 200 coccidioidomycosis-associated deaths reported each year from 1999-2023. Deaths are ...Missing: untreated | Show results with:untreated
[61]
Coccidioidomycosis, USA - BEACON
Aug 8, 2025 · The annual incidence of coccidioidomycosis in the US has increased from 2271 cases in 1998 to 21 171 cases in 2023. Reasons for the increased ...
[62]
Coccidioidomycosis Incidence in Arizona Predicted by Seasonal ...
In Pima County, exposure rates are characterized by two peaks, one in May and the other in September. The average exposure rate for May and September are nearly ...
[63]
Update on the Epidemiology of coccidioidomycosis in the United ...
Jan 25, 2019 · Incidence of coccidioidomycosis increase steadily with age, with those over age 70 experiencing the highest rate at 209 cases per 100,000 ...
[64]
Clinical Overview of Valley Fever - CDC
Coccidioide lives in the soil in the southwestern United States and parts of Mexico, Central America, and South America. Valley fever is considered highly ...Missing: regions | Show results with:regions
[65]
Coccidioidomycosis and Valley Fever - Medscape Reference
Dec 16, 2022 · Coccidioidomycosis is caused by Coccidioides immitis, a soil fungus native to the San Joaquin Valley of California, and by C posadasii.<|control11|><|separator|>
[66]
https://academic.oup.com/mmy/article/57/Supplement_1/S30/5300140
[67]
Valley fever under a changing climate in the United States
The fungus Coccidioides thrives in dry, warm soils with high salt levels, making semi-arid regions with high salinity the optimal growing space (Chow et al., ...
[68]
[PDF] Coccidioidomycosis - Arizona Department of Health Services
These areas have an arid or semi-arid climate with scant rainfall, high summer temperatures and few freezes, conditions ideal for the growth of Coccidioides ...
[69]
[PDF] When to Think Fungus: Coccidioidomycosis - CDC
Patients with positive EIA results in highly endemic areas or with highly suggestive clinical findings (e.g., erythema nodosa), clinicians might start ...
[70]
Review of Clinical and Laboratory Diagnostics for Coccidioidomycosis
Infection generally occurs via the inhalation of airborne arthroconidia, which gives rise to the spherule/endospore phase of infection (1).Missing: process | Show results with:process
[71]
Coccidioidomycosis Complement Fixation Titer Trends in the Age of ...
Nov 27, 2018 · A typical course of infection involves IgM production to levels detectable by immunodiffusion within 1 to 3 weeks of symptom onset, followed ...
[72]
Serologic testing for symptomatic coccidioidomycosis in ... - NIH
Compared with the immunocompetent group, immunosuppressed persons had lower rates of seropositivity for every type of test during the first year after onset of ...
[73]
Review of Clinical and Laboratory Diagnostics for Coccidioidomycosis
Mar 8, 2023 · Among highly immunocompromised individuals, the sensitivity of antibody detection can be as low as 67% (27), so multiple diagnostic modalities, ...
[74]
Development and validation of a quantitative real-time PCR assay ...
... ITS1 region of the rDNA of Coccidioides could reliably detect C. immitis and C. posadasii DNA. The sensitivity of the assay was 1 fg of genomic fungal DNA ...
[75]
Real-time PCR assay for detection and differentiation of ...
Abstract. Coccidioidomycosis (Valley fever) is a pulmonary and systemic fungal disease with increasing incidence and expanding endemic areas.
[76]
IDSA 2016 Clinical Practice Guideline for the Treatment of ...
Jul 27, 2016 · Both erythema nodosum and erythema multiforme occur in coccidioidomycosis. Rheumatologic complaints are typically arthralgias of multiple ...
[77]
[PDF] Coccidioidomycosis Care Guide
Feb 2, 2025 · In most who do develop symptoms, patients will present with a primary pulmonary infection which often resolves without therapy. In about 5 ...<|control11|><|separator|>
[78]
Treatment of Valley Fever - CDC
Apr 24, 2024 · Healthcare providers may prescribe 3-6 months of oral antifungal medication like fluconazole. This is for people with more serious infections or ...Missing: pharmacological | Show results with:pharmacological
[79]
Coccidioidomycosis: Adult and Adolescent OIs - Clinical Info .HIV.gov
Oct 29, 2024 · However, symptoms such as hilar or mediastinal adenopathy, upper lobe infiltrates, nodules, peripheral blood eosinophilia, or rash—all of ...
[80]
Coccidioidomycosis: a growing global concern - PMC
Mar 14, 2025 · In the saprobic phase, Coccidioides transitions from mycelium to arthroconidia. Arthroconidia are released and become airborne by soil ...
[81]
Coccidioidomycosis & Histoplasmosis in Immunocompetent: Review
Sep 1, 2024 · In severe cases, drainage of pericardial effusion may be necessary to alleviate symptoms and prevent further complications [51]. Histoplasmosis ...
[82]
Vertebral coccidioidomycosis with mechanical instability treated ...
Antifungal treatment alone and in combination with spinal surgery (drainage, debridement, and fusion) has a success rate of 58 % and 86 %, respectively [3].Vertebral Coccidioidomycosis... · 2. Case Presentation · 3. Discussion<|separator|>
[83]
Patient outcomes and surgical complications in coccidioidomycosis ...
Jul 25, 2014 · Hydrocephalus due to arachnoid scarring is also a common sequela of coccidioidomycosis and may require CSF diversion via shunting.
[84]
Surgery for Pulmonary Coccidioidomycosis: A 10-Year Experience
Of the 86 patients, 40% underwent resection for persistent symptoms or disease progression despite adequate antifungal therapy. One third of the operations were ...
[85]
Managing Cavitary Coccidioidomycosis Expert Opinions for ...
Dec 13, 2024 · Of those who demonstrate pulmonary coccidioidomycosis, past evidence suggests that approximately 5% to 15% will experience long-term pulmonary ...<|control11|><|separator|>
[86]
Top Questions in the Diagnosis and Treatment of Coccidioidomycosis
Tissue assessment of such nodules, typically done by CT-guided transthoracic needle biopsy, is generally safe and has been demonstrated to have sensitivity ...
[87]
Coccidioidomycosis and Valley Fever Treatment & Management
Dec 16, 2022 · Elevated CF IgG titers and higher-risk ethnicity (eg, Filipino, black ... Pregnancy is a risk factor for disseminated coccidioidomycosis ...
[88]
Valley Fever (Coccidioidomycosis) - Control Prevention - OSHA
Recommendations for Employers · Use water or other material to stabilize soil. · Use tarps to stabilize soil waste piles. · Add landscaping and dust stabilizers to ...Missing: remediation | Show results with:remediation
[89]
Valley Fever - Environmental Health & Safety
Use water, appropriate soil stabilizers and/or re-vegetation to reduce airborne dust. Work upwind from dusty areas when feasible. Suspend work during heavy ...Missing: remediation | Show results with:remediation
[90]
Coccidioidomycosis Outbreak Among Workers Constructing a Solar...
Aug 24, 2018 · Recommendations for employers included 1) reducing dust exposure by ensuring ample and efficient water truck capacity to wet soil; 2) using only ...Missing: percentage | Show results with:percentage
[91]
Surveillance for Coccidioidomycosis, Histoplasmosis, and... - CDC
Aug 19, 2022 · Coccidioidomycosis, histoplasmosis, and blastomycosis are underdiagnosed fungal diseases that often mimic bacterial or viral pneumonia and can cause ...
[92]
detection of Coccidioides from ambient air in Phoenix, Arizona
Sep 10, 2019 · Detection of Coccidioides in air samples collected before and after dust storms. Sixty-three filters were collected daily from 21 sites ...Missing: post- rain
[93]
Coccidioides undetected in soils from agricultural land and ...
May 25, 2023 · Two species of Coccidioides have been identified, C. immitis and C. posadasii [21]. C. immitis is reported from Washington State through the ...
[94]
Overview of the Current Challenges in Pulmonary Coccidioidomycosis
Oct 18, 2024 · Other aspects of post-coccidioidomycosis are secondary to chronic infections such as chronic pulmonary coccidioidomycosis with cavitary disease.
[95]
Operational guidelines (version 1.0) for geological fieldwork in areas ...
Earth scientists working in field areas where Coccidioides immitis is endemic have an increased risk of becoming infected.Missing: 2025 | Show results with:2025
[96]
Reducing Risk for Valley Fever - CDC
Apr 24, 2024 · To reduce risk, avoid dusty areas, use N95 respirators, stay inside during dust storms, avoid soil contact, use air filtration, and clean skin ...Missing: remediation | Show results with:remediation
[97]
Valley Fever Prevention - CDPH - CA.gov
Jun 25, 2024 · If you cannot avoid these dusty areas, or if you must be outdoors in dusty air, consider wearing an N95 respirator (a type of face mask) ...
[98]
USPHS/IDSA Guidelines for the Prevention of Opportunistic ... - CDC
(7) In coccidioidomycosis-endemic areas, when possible, patients should avoid activities associated with in- creased risk, including those involving ...
[99]
Expert Opinion: What To Do When There Is Coccidioides Exposure ...
Here, we emphasize prevention and an approach to a laboratory accident that minimizes the risk of exposure to laboratory staff and staff in adjacent areas.
[100]
what to do when there is Coccidioides exposure in a laboratory
Sep 15, 2009 · Here, we emphasize prevention and an approach to a laboratory accident that minimizes the risk of exposure to laboratory staff and staff in ...
[101]
Valley Fever Center For Excellence: Home
The Valley Fever Center for Excellence is a trusted, educational resource for the public and health care providers.Missing: campaigns incidence reduction
[102]
Valley Fever Awareness, Knowledge, and Perceptions
Oct 2, 2025 · Overall, this study found improving and increasing awareness messaging about Valley fever should be a priority for Arizona public health ...Missing: reduction | Show results with:reduction
[103]
Early History of Coccidioidomycosis: 1892–1945 - Oxford Academic
In 1892, Alejandro Posadas, an intern in Buenos Aires, described a 36-year-old Argentine soldier who had experienced a dermatologic problem since 1889 ...
[104]
Etymologia: Coccidioides - PMC - PubMed Central - NIH
A soil fungus found in the western United States and parts of Mexico and Central and South America, Coccidioides was discovered in 1892 by Alejandro Posadas.
[105]
COCCIDIOIDAL GRANULOMA. - JAMA Network
Ophüls and Moffitt: " A New Pathogenic Mould ," Philadelphia Medical Journal , 1900. 7. " Further Report of a Previously Recorded Case of Blastomycosis of ...
[106]
Coccidioides ecology and genomics - PMC - PubMed Central - NIH
This review details the history of Coccidioides ecological research, and discusses current strategies and advances in understanding Coccidioides genetics and ...
[107]
Coccidioidomycosis: What a long strange trip it's been - PMC
Jan 25, 2019 · Originally considered a protozoan, William Ophüls determined that Coccidioides was a fungus and that the lungs were the apparent initial site of ...
[108]
Molecular and phenotypic description of Coccidioides posadasii sp ...
Jan 31, 2017 · Phylogenetic analyses using single nucleotide polymorphisms, genes, and microsatellites show that C. posadasii represents a divergent, ...
[109]
Full article: Coccidioidomycosis: epidemiology
Jun 25, 2013 · Coccidioidomycosis consists of a spectrum of disease, ranging from a mild, self-limited, febrile illness to severe, life-threatening infection.Ecology · Risk Factors For Infection · Recent Epidemiologic Trends<|control11|><|separator|>